

## INDUCTION OF HYPERTENSION BY VARIOUS ANIMAL MODELS

Manpreet kaur<sup>1</sup>, A.C Rana<sup>1</sup>, Sunil Kumar<sup>1</sup>

<sup>1</sup>Rayat Institute of Pharmacy, SBS Nagar, Ropar-144533, India

\*Corresponding Author Email: [manpi\\_k4ur@yahoo.co.in](mailto:manpi_k4ur@yahoo.co.in)

**Review Article**

**RECEIVED ON 18-08-2011**

**ACCEPTED ON 31-08-2011**

### ABSTRACT

Blood pressure is the pressure of the blood flowing through our blood vessels against vessel walls. It depends on the blood pumped from the heart and elasticity of the blood vessels and varies with age and activity. Hypertension is defined as a diastolic blood pressure of 90mm Hg or higher and systolic blood pressure of 140mm hg or higher. Experimental models of human disease are used to study pathophysiological factors involved in hypertension and assess antihypertensive agents. Today different strains of rats with genetic hypertension are available and in most laboratories, therapeutic studies on hypertension are carried out on these models.

**KEYWORDS:** blood pressure, hypertension, experimental models.

### Introduction

Hypertension is the most common cardiovascular disease and is a major public health issue in developed as well as developing countries. Although it is common and readily detectable, but if left untreated it can often lead to lethal complications. Because of its high incidence and morbidity, various classes of drugs and regimens have been proposed for the control of hypertension. Despite the large armamentaria of drugs being available for the treatment of hypertension, the last two decades have witnessed the introduction of a number of new antihypertensive drugs. Recent research during this period has also added considerably to our knowledge of the mechanisms involved in the pathogenesis of hypertension.

The animal models of hypertension share many features which are common to human hypertension. Many of these models have been developed by utilizing the etiological factors that are presumed to be responsible for human hypertension such as excessive salt intake, hyperactivity of renin angiotensin- aldosterone system (RAAS) and genetic factors. These models are also used in the pharmacological screening of potential antihypertensive agents. In the past, hypertensive animal models have been used infrequently for testing antihypertensive potential

of drugs. As new molecules are being synthesized in a large number, the use of animal models is increasing for testing these molecules. New animal models of hypertension are being developed as new insights in to the pathogenesis of hypertension are revealed.

### DIFFERENT MODELS OF INDUCING HYPERTENSION IN RODENTS:

The various types of animal models of hypertension are:

1. Renovascular hypertension
2. Dietary hypertension
3. Endocrine hypertension
4. Neurogenic hypertension
5. Psychogenic hypertension
6. Genetic hypertension
7. Other models

### RENOVASCULAR HYPERTENSION:

**Goldblatt method<sup>1</sup>:** It was reported that a partial constriction of renal arteries in dogs produced hypertension. This type of hypertension has also

been induced in rabbits, rats and monkeys. A U-shaped silver ribbon clip is used to constrict the renal arteries in rabbits and rats.

1. **Three types of hypertension are produced by Goldblatt method:**

• **Two kidney one clip (2K1C) hypertension**<sup>1, 2, 3</sup>

The renal artery is constricted on only one side with the other artery (or kidney) left untouched which causes sustained increase in BP due to increased plasma renin activity (PRA), which in turn increases circulating angiotensin-II, a potent vasoconstrictor. However, there is no salt and water retention because of the other normal kidney being intact. Therefore, the resultant hypertension at this stage is renin-angiotensin dependent. After about 6 weeks, the increased angiotensin-II releases aldosterone from adrenal cortex leading to a gradual retention of salt and water. Decreased renin production is because of the retention of salt and water. From this stage onwards, hypertension is volume dependent. This clearly shows that salt and water balance is critically involved in the pathogenesis of renovascular hypertension. Increased BP and increased renin activity returns to normal by unclipping or removal of the affected kidney.

• **One kidney one clip (1K1C) hypertension**<sup>1, 2, 3</sup>

Constriction of renal artery is done on one side and the contralateral kidney is removed. BP rises within few hours. As there is no other kidney, there is no pressure diuresis and natriuresis, so rapid salt and water retention is there. Plasma renin activity is usually normal. Hypertension soon becomes volume dependent

• **Two kidney two clip (2K2C) hypertension**<sup>2</sup>:

Constriction of aorta or both renal arteries is done. There is a patchy ischemic kidney tissue, which secretes renin causing increased BP. The remaining kidney tissue retains salt and water. In fact, one of the most common causes of renal hypertension in human beings is such a patchy ischemic kidney disease.

2. **Hypertension induced by external compression of renal parenchyma:** This type of hypertension is produced in dogs, rabbits

and rats. The following methods are used to produce this type of hypertension:

• **Page hypertension**<sup>3, 4, 5</sup> : A sheet of cellophane is covered around the kidney and held in place by silk sutures tied loosely around the renal hilus. Both kidneys are wrapped or one kidney is wrapped and other is removed. A fibrocollagenous shell is formed around the kidney in 3-5 days because of reaction of the tissue to the foreign material. Renal vascular pressure is decreased due to the shell compressing renal parenchyma. This expands the extracellular volume leading to increased peripheral resistance and hence increased BP.

• **Grollman hypertension**<sup>6</sup> : In this method, kidney tissue is compressed by securing a 'figure of 8' ligature around the kidney. The ligature around the kidney forms a figure resembling number 8. This type of hypertension can be produced in dogs, rabbits and rats. It is of two types:

1. Two kidney one ligature (2K1L)
2. One kidney one ligature (1K1L)

3. **Coarctation of aorta**<sup>7, 8, 9</sup> : Renal blood flow can be decreased by compressing the aorta. Coarctation can be done just above the renal arteries, between renal arteries and superior mesenteric arteries or between two renal arteries with the right artery above and the left artery below the site of coarctation. An increase in BP similar to 2K1C model can be produced by applying a rubber band to abdominal aorta along with constriction of right renal artery for 8 weeks. Coarctation can be followed by unilateral nephrectomy to produce this type of hypertension.

4. **Reduced renal mass**<sup>10</sup> : Reducing renal tissue to five-sixth (5/6th) by renal mass ablation produces hypertension. The right kidney is removed and 2 or 3 branches of left renal artery are ligated to produce infarction of approximately 2/3rd of the left kidney in this method.

**DIETARY HYPERTENSION:**

1. **Increased salt intake**<sup>11</sup> : Physiologically, normal kidney has the ability to excrete easily the daily salt load without allowing a marked rise in

extracellular volume. Excess salt intake produces hypertension in rats, which mimics human hypertension. High salt intake hypertension has been produced in rats, rabbits and chicks by replacing drinking water with 1-2% sodium chloride for 9-12 months.

#### ENDOCRINE HYPERTENSION:

1. **Mineralocorticoid induced hypertension**<sup>11, 12, 13, 14, 15</sup> : It was first demonstrated that deoxycorticosterone acetate (DOCA) produces hypertension in rats. Increased blood volume and hence increased BP is due to increased DOCA-induced reabsorption of salt and water. Vasopressin secretion is increased leading to water retention and vasoconstriction. Additionally, altered activity of RAAS leads to increased sympathetic activity. Rats are prone to DOCA-salt induced hypertension. This type of hypertension can also be produced in dogs and pigs. Other mineralocorticoids (e.g., aldosterone) and glucocorticoids can also produce this type of hypertension.
2. **Adrenal regeneration hypertension**<sup>16</sup> : Hypertension is produced in rats by unilateral nephrectomy followed by removal of right adrenal gland and enucleation of left adrenal gland. Enucleation is carried out by making a small incision in the capsule of adrenal gland through which the bulk of glandular tissue is extruded by gentle application of pressure with curved forceps. Drinking water is replaced with 1% saline. Hypertension develops during regeneration of adrenal glands in about 2 weeks.

#### NEUROGENIC HYPERTENSION

1. **Denervation of sinoaortic baroreceptors**<sup>2, 16, 17</sup>: This is the most often used neurogenic model of hypertension. In dogs, cardioaortic nerve is located at the junction of superior laryngeal and vagus nerve and runs in the form of several fine strands. These strands unite and may be traced back as a white band lying within the vagal sheath alongside the cervical sympathetic nerve. Following bilateral vagotomy and carotid sinus denervation, the

region is painted with 5% phenol and then alcohol to ensure complete denervation of the carotid sinus. There is sudden increase in BP. The dog is allowed to equilibrate for approximately 30 min and a bolus of the test compound can be given by intravenous administration. BP returns to normal within about 2 days because the response of vasomotor center to the absent baroreceptors signals fades away, which is called "resetting of baroreceptors". Thus, this is only an acute type of hypertension.

#### PSYCHOGENIC HYPERTENSION<sup>18, 19, 20</sup>

Reports depict that elevation of BP resulting from repeated exposure to stressful situation may lead to a state of persistent hypertension. Borderline hypertensive rats (BHR) are useful for psychogenic hypertension. BHRs that were exposed to daily sessions of either short (20 min) or long (120 min) duration air-jet stimulation developed hypertension within 2 weeks in comparison to home cage controls. Animals exposed to 120 min stress sessions had significantly higher systolic BP relative to the 20 minute group.

#### GENETIC HYPERTENSION<sup>21, 22, 23, 24</sup>

In 1963, Okamoto and Aoki introduced a new model of experimental hypertension that required no physiological, pharmacological or surgical intervention. The so called 'spontaneous hypertensive rat (SHR)' was developed by meticulous genetic inbreeding that uniformly resulted in 100% of the progeny having naturally occurring hypertension.

#### OTHER MODELS:

1. **Obesity related hypertension**<sup>25</sup> : Wistar fatty rats (WFR) derived from cross between obese Zucker and Wistar Kyoto rats show persistent hyperinsulinemia and hypertension after 16 weeks of age and may be a good model to elucidate the relationship between hyperinsulinemia and hypertension.
2. **Hypertension induced by cholinomimetic agents**<sup>26, 27</sup>: Physostigmine (10-80 µg/kg, *i.v.*), a cholinesterase inhibitor, and oxotremorine (20-40

µg/kg, *i.v.*), a direct muscarinic cholinergic agonist, cause a dose-dependent increase in BP. The cholinomimetic-induced hypertension has been shown to be elicited through activation of central cholinergic mechanism and mediated peripherally through sympathetic nervous system.

**3. Angiotensin-II induced hypertension<sup>28, 29</sup> :** Subcutaneous infusion of angiotensin-II (0.7 mg/kg/day) using mini pump elicits hypertension in 4-8 weeks.

**4. Hypertension induced by cadmium<sup>12</sup>:** Hypertension is produced by the chronic administration of CdCl (1 mg/kg/day, *i.p.* for 2 wk). CdCl-induced hypertension might be due to the fact that the metal ion might mimic Ca<sup>2+</sup> ion as a partial agonist and produce a direct contractile effect on vascular smooth muscle.

**5. Chronic nitric oxide inhibition-induced hypertension:**

**• L-NAME model of inducing hypertension:**

The endothelium is a single-cell layer that lines all arteries and veins. It contributes to the tone of vascular smooth muscle (VSM) and mediates vasodilation in response to various stimuli including shear stress and the neurotransmitter, acetylcholine (ACh).<sup>30</sup> ACh binds to muscarinic cholinergic receptors located in the endothelial cell membrane which initiates the synthesis and release of the autocooid, nitric oxide (NO). Since cell membranes are permeable to small, gaseous molecules, NO readily diffuses into the adjacent VSM cells resulting in relaxation. This relaxation is achieved through the cGMP second messenger system that leads to activation of calcium pumps embedded in the plasma membrane and sarcoplasmic reticulum. The calcium pumps effectively lower the intracellular calcium concentration causing relaxation of VSM and dilation of the blood vessels.<sup>31</sup>

NO is produced in the body by endothelial cells as well as by activated macrophages and neutrophils. NO is synthesized by the enzyme, nitric oxide synthase (NOS), through the deamination of the amino acid, L-arginine.<sup>32</sup> After NO is synthesized, this small, hydrophobic molecule diffuses into

neighbouring cells. Due to its short half-life (5 to 10 seconds), it acts only locally because it is converted to nitrates and nitrites by oxygen and water in the extracellular space.<sup>33</sup> Once NO reaches the VSM cell cytosol, it reacts with iron in the active site of the enzyme guanylyl cyclase. This stimulates the production of the intracellular mediator cGMP which greatly amplifies the signal.<sup>34</sup>

The endothelium synthesizes NO incorporating the terminal guanidino nitrogen of L-arginine. Synthesis of NO is an enantiomer-specific reaction and is inhibited *in vitro* by N $\omega$ -monomethyl-L-arginine (L-NMMA), but not its D-enantiomer.<sup>35</sup> Other experiments showed NOS is also inhibited by N-iminoethyl-L-ornithine (L-NIO) and N $\omega$ -nitro-L-arginine methyl ester (L-NAME) in the adrenal gland<sup>36</sup> and brain.<sup>37</sup>

eNOS is inhibited by guanidino substituted analogues of L-arginine such as L-NMMA, L-NIO and L-NAME. These analogues, both *in vivo* and *in vitro*, compete with L-arginine for binding sites on eNOS, resulting in inhibition of NO synthesis.<sup>38</sup> Administration of L-NAME results in hypertension and serves as an excellent model for *in vivo* study because it is orally active. Aside from the action of L-NAME to competitively inhibit eNOS, other L-NAME actions may influence blood pressure (BP). L-NAME may limit NO production by acting as a muscarinic receptor antagonist.<sup>39</sup>

**Conclusion:**

The present review opens vista for the induction of hypertension in various animal models.

**Acknowledgement:**

I express my thanks to rayat and bahra group and to the chairman of the college S. Gurvinder Singh Bahra and S. Nirmal Singh Rayat for providing supportive and friendly atmosphere and exposure to the scientific world and a platform to rise.

I convey my intense gratitude to Dr. A.C Rana, Professor Department of pharmacology and Diector Rayat college of Pharmacy, Railmajra, Punjab.

## REFERENCES:

1. Goldblatt H., Direct determination of systemic blood pressure and production of hypertension in rabbit. *Proc Soc Exp Bio Med*, 105: 213-6, (1960)
2. Ganong WF. Review of medical physiology. London: Prentice Hall International Inc, 19, (1999)
3. Guyton AC, Hall JE, Ed. Textbook of Medical Physiology. Noida: WB Saunders Company, 9, (1998)
4. Page IH., The production of persistent arterial hypertension by cellophane perinephritis. *Journal of American Medical Association*, 113 :2046, (1939)
5. Roberts-Thomson P, McRitchie RJ, Chalmers JP., Experimental hypertension produces diverse changes in the regional vascular responses to endothelin-1 in the rabbit and the rat. *Journal of Hypertension*, 12: 1225-34, (1994)
6. Grollman A., The effect of various hypotensive agents on the arterial blood pressure of hypertensive rats and dogs. *Journal of Pharmacology and Experimental Therapeutics*, 174 :263-70, (1955)
7. Thiedemann KU, Holubarsch C, Medugarac I, Jacob R., Connective tissue contraction and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical and mechanical parameters. *Basic Research in Cardiology*, 78: 140-55, (1983)
8. Brilla CG, Pick P, tan LB, Janicki JS, Weber KT., Remodelling of rat right and left ventricle in experimental hypertension. *Circulation Research*, 67: 1355-64, (1990)
9. Gabel RA, Kivlighn SD, Siegl PK., The effect of chronically administered L-158,809 on the development of hypertension in sub totally nephrectomised Munich Wistar rats. *FASEB Journal*, 6 :982, (1992)
10. Anderson S, Meyer TW, Rennke HG, Brenner BM., Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. *Journal of Clinical Investigation*, 76: 612-9 (1985)
11. Dahl LK. Possible role of salt intake in the development of essential hypertension. In: Pork KD, Cottier PT, Ed. Essential hypertension-an international symposium. Berlin:Springer-Verlag, 53-65 (1960)
12. Rathod SP, Shah N, Balaraman R., Antihypertensive effect of dietary calcium and diltiazem, a calcium channel blocker on experimentally induced hypertensive rats. *Indian Journal of Pharmacology*, 29 :99-104 (1997)
13. Seyle H, Bois P., The hormonal production of nephrosclerosis and periarteritis nodosa in the primate. *British Medical Journal*, 1: 183-6 (1957)
14. Hakim ZS, Goyal RK., Comparative evaluation of different rat models with coexisting diabetes mellitus and hypertension. *Indian Journal of Physiology and Pharmacology*, 44: 125- 35 (2000)
15. Knowlton AI, Loeb EN, Stoerk HC, White JP, Heffernan JF., Induction of arterial hypertension in normal and adrenalectomised rats given cortisone acetate. *Journal of Experimental Medicine*, 96: 187-205 (1952)
16. Boura ALA, Green AF, Ed. Antihypertensive agents. In: Laurence DR, Bacharach AL. Evaluation of drug activities pharmacometrics. London: Academic Press, 1 :431-53 (1964)
17. Sharma ML., Antihypertensive activity of scopolamine. *Indian Journal of Pharmacology*, 17: 219-22 (1985)
18. Hatton DC, De Merritt J, Coste SC, McCarron DA., Stress induced hypertension in the borderline hypertensive rat: stimulus duration. *Physiology and Behaviour*, 53 :635-41 (1993)
19. Henry JP, Liu YY, Nadra WE, Qian CG, Mormede P, Lemaire V, et al. Psychosocial stress can induce chronic hypertension in normotensive strains of rats. *Hypertension*, 21: 714-23 (1993)
20. Lawler JE, Barker GF, Hubbard JW, Cox RH, Randall GW., Blood pressure and plasma renin activity responses to chronic stress in the borderline hypertensive rat. *Physiology and Behaviour*, 32: 101-5 (1984)
21. Okamoto K, Aoki K., Development of a strain of spontaneously hypertensive rats. *Japanese Circulation Journal*, 27: 282-93 (1963)
22. Kurtz TW, Castro R, Simonet L, Printz MP. Biometric genetic analysis of blood pressure in the spontaneously hypertensive rat. *Hypertension*, 16: 718-24 (1990)
23. Buccafusco JJ., The role of central cholinergic neurons in the regulation of blood pressure and in

- experimental hypertension. *Pharmacology Reviews*, 48: 179-211 (1996)
24. Horan MJ, Lovenberg W. Genetic rat models for hypertension: guidelines for breeding, care and use. *Journal of Hypertension*, 4: 7-9 (1986)
25. Yamakawa T, Tanaka S, Tamura K, Isoda F, Ukawa K, Yamakura Y, et al. Wistar fatty rat is obese and spontaneously hypertensive. *Hypertension*, 25: 146-50 (1995)
26. Ozkutlu U, Onat F, Aslan AN, Oktay S., Central muscarinic M2 cholinergic receptors involved in cholinergic hypertension. *European Journal of Pharmacology*, 250: 349-54 (1993)
27. Smith EC, Padnos B, Cordon CJ., Peripheral versus central muscarinic effects on blood pressure, cardiac contractility heart rate, and body temperature in the rat monitored by radio telemetry. *Pharmacology and Toxicology*, 89: 35-42 (2001)
28. Gorbea-Oppliger C, Kanagy NL, Fink GD., Losartan (DuP753) reverses angiotensin-induced hypertension in conscious rats. *FASEB Journal*, 6: 1810 (1992)
29. Kregel SH, Hodgin JB, Hagaman JR, Smithies O., A non invasive computerized tail-cuff system for measuring blood pressure in mice. *Hypertension*, 25: 1111-5 (1995)
30. Furchgott RF, Zawadzki JV., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*, 288: 373-76 (1980)
31. Shepherd JT, Katusic ZS. Endothelium-derived vasoactive factors. *Hypertension*, 18: 76-85 (1991)
32. Forstermann U, Nakan M, Tracey WR, Pollock JS., Isoforms of nitric oxide synthase: functions in the cardiovascular system. *European Heart Journal*, 14 :10- 15 (1993)
33. Wink DA, Darbyshire JF, Nims RW, Saavedra JE, Ford PC., Reactions of bioregulatory agent nitric oxide in oxygenated aqueous media: determination of the kinetics for oxidation and nitrosation by intermediates generated in the NO/O<sub>2</sub> reaction. *Chemical Research in Toxicology*, 6: 23-27 (1993)
34. Lamb TD, Pugh EN Jr., G-protein cascades: gain and kinetics. *Trends in Neuroscience*, 15: 291-98 (1992)
35. Palmer RMJ, Ashton DS, Moncada S., Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature*, 333 :664-66 (1988)
36. Palacios M, Knowles RG, Palmer RMJ, Moncada S., Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. *Biochem. Biophys. Res. Commun*, 165: 802-9 (1989)
37. Knowles RG, Palacios M, Palmer RMJ, Moncada S., Kinetic characteristics of nitric oxide synthase from rat brain. *Biochemical Journal*, 269: 207-210 (1990)
38. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S., Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. *British Journal of Pharmacology*, 101 :746-52 (1990)
39. Buxton ILO, Cheek DJ, Eckman D, Westfall DP, Sanders KM, Keef KD., N<sup>G</sup>-nitro L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. *Circulation Research*, 72:387-95 (1993).

**\*Address for the Correspondence:****Manpreet kaur****Rayat Institute of Pharmacy (Ropar)**

Contact no: 09988321955

Email: manpi\_k4ur@yahoo.co.in